BACKGROUND AND PURPOSE: High blood pressure is common in the acute phase of stroke and is associated with poor outcome. We examined whether blood pressure-lowering treatment with candesartan in the acute phase affects long-term cognitive function and quality of life. METHODS: Scandinavian Candesartan Acute Stroke Trial was a randomized-controlled and placebo-controlled trial of candesartan in 2029 patients with acute stroke and raised blood pressure. At 6 months, cognitive function was assessed by the Mini Mental State Examination and quality of life by the EuroQol instrument. We used ordinal logistic and multiple linear regression for statistical analysis, adjusting for predefined key variables. RESULTS:Median Mini Mental State Examination score was 28 in both groups, and there was no significant difference between the distribution of Mini Mental State Examination scores in the 2 groups (common odds ratio, 1.11; 95% confidence interval, 0.91-1.34; P=0.32). Median EuroQol-5D index were 0.74 and 0.78 (P=0.034), and the mean EuroQol-visual analogue scale scores were 66.0 and 67.3 in the candesartan and placebo groups, respectively (P=0.11). CONCLUSIONS:Candesartan did not improve cognitive function or quality of life. Rather, there were signs of harmful effects. These findings support the conclusion from our previous report that there is no indication for routine blood pressure-lowering treatment with candesartan in the acute phase of stroke. CLINICAL TRIAL REGISTRATION URL: www.clinicaltrials.gov. Unique identifier: NCT00120003.
RCT Entities:
BACKGROUND AND PURPOSE: High blood pressure is common in the acute phase of stroke and is associated with poor outcome. We examined whether blood pressure-lowering treatment with candesartan in the acute phase affects long-term cognitive function and quality of life. METHODS: Scandinavian CandesartanAcute Stroke Trial was a randomized-controlled and placebo-controlled trial of candesartan in 2029 patients with acute stroke and raised blood pressure. At 6 months, cognitive function was assessed by the Mini Mental State Examination and quality of life by the EuroQol instrument. We used ordinal logistic and multiple linear regression for statistical analysis, adjusting for predefined key variables. RESULTS: Median Mini Mental State Examination score was 28 in both groups, and there was no significant difference between the distribution of Mini Mental State Examination scores in the 2 groups (common odds ratio, 1.11; 95% confidence interval, 0.91-1.34; P=0.32). Median EuroQol-5D index were 0.74 and 0.78 (P=0.034), and the mean EuroQol-visual analogue scale scores were 66.0 and 67.3 in the candesartan and placebo groups, respectively (P=0.11). CONCLUSIONS:Candesartan did not improve cognitive function or quality of life. Rather, there were signs of harmful effects. These findings support the conclusion from our previous report that there is no indication for routine blood pressure-lowering treatment with candesartan in the acute phase of stroke. CLINICAL TRIAL REGISTRATION URL: www.clinicaltrials.gov. Unique identifier: NCT00120003.
Entities:
Keywords:
Acute stroke; Candesartan; Cognition; Hypertension; Quality of life
Authors: Costantino Iadecola; Kristine Yaffe; José Biller; Lisa C Bratzke; Frank M Faraci; Philip B Gorelick; Martha Gulati; Hooman Kamel; David S Knopman; Lenore J Launer; Jane S Saczynski; Sudha Seshadri; Adina Zeki Al Hazzouri Journal: Hypertension Date: 2016-10-10 Impact factor: 10.190
Authors: Milija D Mijajlović; Aleksandra Pavlović; Michael Brainin; Wolf-Dieter Heiss; Terence J Quinn; Hege B Ihle-Hansen; Dirk M Hermann; Einor Ben Assayag; Edo Richard; Alexander Thiel; Efrat Kliper; Yong-Il Shin; Yun-Hee Kim; SeongHye Choi; San Jung; Yeong-Bae Lee; Osman Sinanović; Deborah A Levine; Ilana Schlesinger; Gillian Mead; Vuk Milošević; Didier Leys; Guri Hagberg; Marie Helene Ursin; Yvonne Teuschl; Semyon Prokopenko; Elena Mozheyko; Anna Bezdenezhnykh; Karl Matz; Vuk Aleksić; DafinFior Muresanu; Amos D Korczyn; Natan M Bornstein Journal: BMC Med Date: 2017-01-18 Impact factor: 8.775
Authors: Emer R McGrath; Alexa S Beiser; Charles DeCarli; Kendra L Plourde; Ramachandran S Vasan; Steven M Greenberg; Sudha Seshadri Journal: Neurology Date: 2017-11-08 Impact factor: 9.910
Authors: Jose Alvarez-Sabín; Estevo Santamarina; Olga Maisterra; Carlos Jacas; Carlos Molina; Manuel Quintana Journal: Int J Mol Sci Date: 2016-03-16 Impact factor: 5.923